trial

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

NCTId NCT01568203
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 50 (actual)
Sponsored by Amgen
Primary completion 2012-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-09
Primary completion
2012-06
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
AMG 579

Sponsors

AmgenLead Sponsor

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE1
Primary Completion Date
2012-06
Status
TERMINATED
relationships
The graph out of here
drug
AMG 579
drug
lead_sponsor
Amgen
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication